In general, GH RT is contraindicated in patients with an ACTIVE malignancy. My practice is not to treat until I have 5 years of cancer-free interval. The situation is different with pituitary adenomas and craniopharyngiomas, as there is literature showing that GHRT does not increase the risk of recu...